dipyridamole has been researched along with Hepatic Failure in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abele, JT | 1 |
| Raubenheimer, M | 1 |
| Bain, VG | 1 |
| Wandzilak, G | 1 |
| AlHulaimi, N | 1 |
| Coulden, R | 1 |
| deKemp, RA | 1 |
| Klein, R | 1 |
| Williams, RG | 1 |
| Warshawski, RS | 1 |
| Lalonde, LD | 1 |
1 other study available for dipyridamole and Hepatic Failure
| Article | Year |
|---|---|
Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using
Topics: Adult; Aged; Coronary Circulation; Dipyridamole; Dobutamine; End Stage Liver Disease; Female; Humans | 2020 |